Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),General Medicine
Reference45 articles.
1. Hallek M, Fischer K, Fingerle-Rowson G, et al. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial. Lancet. 2010;376(9747):1164–74.
2. Eichhorst B, Robak T, Montserrat E, et al. Chronic lymphocytic leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2015;26(suppl 5):v78–84.
3. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Non-Hodgkin’s lymphoma. Version 1.2016. http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site . Last accessed December, 2015.
4. Knauf W, Re D. Chronic lymphocytic leukemia: raising expectations in the treatment of elderly patients. J Leuk. 2015;3(2):1–8.
5. Keating MJ, O’Brien S, Albitar M, et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia. J Clin Oncol. 2005;23(18):4079–88.
Cited by
12 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献